Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs Transocean Ltd (RIG) Price & Performance

Eli Lilly And CoTrade
Transocean LtdTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs Transocean Ltd — how do they compare? Eli Lilly And Co trades at $1,214.52 (market cap $1.10T), while Transocean Ltd trades at $5.85 (market cap $6.39B). The key difference: Eli Lilly And Co is far larger — about 172.1× Transocean Ltd's market cap, and Eli Lilly And Co pays a 0.56% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals.

LLYRIG
Market Cap
$1.10T$6.39B
Sector
HealthTechnology
52-Week High
$1.24K$7.58
52-Week Low
$639.43$2.80
Enterprise Value
$1.14T$11.00B
Dividend Yield
0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

Transocean Ltd

Transocean (RIG) trades at $5.26, up 1.94% with neutral technical signals. The company shows mixed fundamentals with strong revenue growth to $4.1B in 2026 but persistent net losses improving to -$1.7B. Recent Q2 2026 earnings beat expectations with $0.03 EPS, and the company secured a significant $1B+ contract with Equinor, boosting long-term visibility. Analyst sentiment is divided with 39% buy ratings, while institutional activity shows mixed positioning with recent large acquisitions by Elliott Investment Management.

RIG presents a turnaround opportunity with improving operational metrics and contract wins, but significant execution risks remain. The pending Valaris merger could create synergies, though current negative profitability and high debt require careful monitoring. The stock offers speculative upside if operational improvements continue, but investors should weigh the substantial losses against the company's market position and backlog growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About Transocean Ltd

Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.

Read more on RIG